Filing Analysis
OrthoPediatrics Corp. filed an 8-K to provide notice of upcoming investor presentations under Regulation FD. The filing includes an investor presentation dated November 2024 as Exhibit 99.1.
📋 Key Facts
- The company intends to use the information in Exhibit 99.1 for upcoming presentations to investors and analysts.
- Filing date: November 12, 2024.
- Exhibit 99.1 contains an Investor Presentation dated November 2024.
OrthoPediatrics Corp. filed an 8-K to announce its quarterly earnings results for the period ending September 30, 2024. The filing serves as a formal announcement of financial performance and includes unaudited condensed consolidated financial statements.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing contains unaudited condensed consolidated financial statements as of and for the quarter ended September 30, 2024.
- Earnings results were released via press release (Exhibit 99.1).
OrthoPediatrics Corp. entered into new employment agreements for its five Named Executive Officers (NEOs) on October 15, 2024. These agreements supersede previous contracts and include updated base salaries, bonus participation, and significant severance provisions.
🚩 Red Flags
- Significant severance packages (30 months salary + 2.5x bonus) create substantial potential liabilities in the event of leadership turnover or acquisition.
📋 Key Facts
- New employment agreements signed with CEO David R. Bailey ($550k salary), CFO Fred L. Hite ($501k salary), President of Scoliosis Gregory A. Odle ($368k salary), General Counsel Daniel J. Gerritzen ($368k salary), and President of Trauma Joseph W. Hauser ($400k salary).
- Agreements have an initial three-year term with automatic one-year renewals.
- Severance includes 30 months of base salary plus 2.5x the average bonus from the previous three fiscal years.
- Non-competition covenants restrict solicitation and competition for 30 months post-termination.
- Severance benefits are triggered by termination without 'Cause', 'Good Reason', or a Change of Control.
OrthoPediatrics Corp. filed an 8-K to provide notice of upcoming investor presentations under Regulation FD. The filing includes an updated investor presentation dated September 2024 as Exhibit 99.1.
📋 Key Facts
- The company intends to use the information in Exhibit 99.1 for upcoming presentations to investors and analysts.
- Exhibit 99.1 contains an Investor Presentation dated September 2024.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
OrthoPediatrics Corp. has closed a $25 million term loan and issued $50 million in 4.75% Convertible Senior Notes due 2030 to Braidwell Transaction Holdings LLC. The transaction includes the potential issuance of up to 1,691,470 shares of common stock upon conversion.
🚩 Red Flags
- Potential dilution of existing shareholders through the conversion of senior notes (up to ~1.69M shares).
- Increased debt load via a $25M term loan and $50M in convertible notes.
📋 Key Facts
- Closed a $25,000,000 Initial Term Loan Commitment on August 12, 2024.
- Issued $50,000,000 in aggregate principal amount of 4.75% Convertible Senior Notes due February 15, 2030.
- Notes were issued to Braidwell Transaction Holdings LLC – Series 10 via a private placement (Section 4(a)(2)).
- Initial maximum conversion rate is 33.8294 shares per $1,000 principal amount.
- Maximum potential share issuance upon conversion is 1,691,470 shares.
OrthoPediatrics Corp. filed an 8-K to provide notice of upcoming investor presentations under Regulation FD. The filing includes an updated investor presentation dated August 2024 as Exhibit 99.1.
📋 Key Facts
- The company is providing disclosure pursuant to Item 7.01 (Regulation FD Disclosure).
- Executive officers have upcoming presentations scheduled for investors and analysts.
- An investor presentation dated August 2024 has been attached as Exhibit 99.1.
OrthoPediatrics Corp. filed an 8-K to announce its quarterly earnings results for the period ended June 30, 2024. The filing serves as a formal notice that financial statements and a press release have been issued.
📋 Key Facts
- Report date: August 5, 2024
- Reporting period: Quarter ended June 30, 2024
- The company furnished unaudited condensed consolidated financial statements as of and for the quarter ended June 30, 2024.
- Earnings results were released via press release (Exhibit 99.1).
OrthoPediatrics Corp. entered into a $25 million term loan agreement and a $50 million convertible senior notes offering on August 5, 2024. The company intends to use the proceeds for debt repayment, transaction fees, stock repurchases (up to $5M), and working capital.
🚩 Red Flags
- Significant increase in total debt load ($75M total potential facility/notes).
- Secured debt involves granting a first priority security interest in substantially all assets and intellectual property.
- Convertible notes include 'Fundamental Change' provisions that may trigger repurchase requirements upon de-listing or certain mergers.
- Restrictive covenants in the Term Loan Agreement regarding dividends, acquisitions, and incurring additional indebtedness.
📋 Key Facts
- Entered into a Term Loan Agreement with Braidwell LP as lenders; initial principal of $25.0 million plus a $25.0 million delayed draw term loan facility (DDTL).
- Term Loan interest rate is SOFR + 6.50% (with a 3.25% floor), with an option for 1.00% pay-in-kind interest.
- Term Loan maturity date is August 5, 2029; no amortization required until then.
- Issued $50.0 million in 4.75% Convertible Senior Notes due February 15, 2030 to Braidwell Transaction Holdings LLC – Series 10.
- Initial conversion price for the notes is approximately $40.98 per share (conversion rate of 24.4021 shares per $1,000).
- Term Loan provides a first priority security interest in substantially all company assets, including intellectual property.
OrthoPediatrics Corp. held its 2024 Annual Meeting of Stockholders on May 24, 2024. The meeting resulted in the election of three directors and the approval of several key shareholder matters including executive compensation and auditor appointment.
📋 Key Facts
- Annual Meeting held on May 24, 2024.
- David R. Bailey, Marie C. Infante, and Jimmy D. McDonald were elected to the Board of Directors for terms lasting until the 2027 Annual Meeting.
- Stockholders approved the compensation of named executive officers (Say-on-Pay) on an advisory basis.
- The OrthoPediatrics Corp. 2024 Incentive Award Plan was approved by stockholders.
- Deloitte & Touche LLP was approved as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
OrthoPediatrics Corp. announced that stockholders approved the 2024 Incentive Award Plan during the company's Annual Meeting of Stockholders held on May 24, 2024. This new plan replaces the 2017 Incentive Award Plan and is designed to facilitate equity-based compensation for directors, employees, and advisors.
📋 Key Facts
- Stockholders approved the 2024 Incentive Award Plan at the Annual Meeting on May 24, 2024.
- The 2024 Plan serves as a successor to the 2017 Incentive Award Plan.
- No further awards will be granted under the 2017 Plan following this approval.
- The plan is intended to align interests of directors, employees, and advisors with stockholders.
OrthoPediatrics Corp. filed an 8-K to provide notice of upcoming investor presentations under Regulation FD. The filing includes an updated investor presentation dated May 2024 as Exhibit 99.1.
📋 Key Facts
- The company intends to use the attached investor presentation in upcoming meetings with analysts and investors.
- Filing date: May 8, 2024.
- Exhibit 99.1 contains the Investor Presentation dated May 2024.
OrthoPediatrics Corp. filed an 8-K to announce its quarterly earnings results for the period ended March 31, 2024. The filing serves as a formal announcement of financial performance and includes unaudited condensed consolidated financial statements.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is an announcement of results of operations and financial condition (Item 2.02).
- Financial statements are provided as Exhibit 99.1.
OrthoPediatrics Corp. filed an 8-K to provide notice of upcoming investor presentations under Regulation FD. The filing includes an investor presentation as Exhibit 99.1.
📋 Key Facts
- The company plans to use the attached investor presentation (Exhibit 99.1) in upcoming meetings with analysts and investors.
- Filing date: March 11, 2024.
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
OrthoPediatrics Corp. filed an 8-K to announce its earnings results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal announcement of financial performance via an attached press release.
📋 Key Facts
- Report date: March 6, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes unaudited condensed consolidated financial statements as of and for the quarter and year ended Dec 31, 2023.
- Information is furnished pursuant to Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
OrthoPediatrics Corp. issued a press release providing preliminary unaudited net revenue results for Q4 and the full year 2023, alongside management's projections for 2024 revenue.
🚩 Red Flags
- Preliminary results are subject to audit and may differ materially from final figures
📋 Key Facts
- Reported date: January 8, 2024
- Released preliminary unaudited net revenue for Q4 and FY 2023
- Provided management's projection of 2024 net revenue
- Included a business update via investor presentation (Exhibit 99.2)
OrthoPediatrics Corp. entered into a definitive agreement to acquire Boston Brace International, Inc., a manufacturer of pediatric orthotic and prosthetic devices, for $22 million in cash. The acquisition includes the issuance of restricted stock awards to approximately 170 individuals as part of the transaction.
🚩 Red Flags
- The transaction involves significant cash outlay ($22M) which may impact liquidity depending on the company's current cash position (not specified in 8-K).
📋 Key Facts
- Acquisition date: January 5, 2024
- Target company: Boston Brace International, Inc.
- Total cash consideration: $22 million (subject to customary adjustments)
- Equity component: Approximately 83,000 shares of restricted stock granted to ~170 individuals, valued at ~$2.5 million based on a share price of $30.12
- Target business focus: Pediatric orthotic and prosthetic devices, including non-surgical scoliosis treatment.
OrthoPediatrics Corp. entered into an $80 million Credit, Security and Guaranty Agreement on December 29, 2023. The facility consists of a $30 million term loan (issued in three $10 million tranches) and a $50 million revolving credit facility to replace an existing $50 million Squadron Capital LLC loan.
🚩 Red Flags
- Debt includes specific acceleration triggers related to changes in control, board composition (majority change over 12 months), or significant stock ownership changes (35%+).
- The debt is secured by a security interest in the Company's assets.
📋 Key Facts
- Total aggregate principal amount: $80 million.
- Structure: $30 million Term Loan (three $10M tranches) and $50 million Revolving Loan.
- Term Loan interest rate: Greater of One Month Term SOFR + 6.50% or 9.0%.
- Revolving Loan interest rate: Greater of One Month Term SOFR + 4.0% or 6.50%.
- Maturity date for Term Loan: December 1, 2028 (subject to acceleration events).
- The facility replaces the existing $50 million Squadron Capital LLC revolving credit facility.
- Loans are secured by a security interest in the Company's and other Borrowers' assets.